Apyx Medical (APYX) AI Stock Analysis

• Market Cap: $72.19M
• Dividend Yield: N/A
• Average Volume (3M): 110.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.19
• Revenue Growth: -6.27%
• EPS Growth: 16.76%
• Country: US
• Employees: 220
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): -0.10
• Shares Outstanding: 37,793,884
• 10 Day Avg. Volume: 115,022
• 30 Day Avg. Volume: 110,372
• PEG Ratio: -0.29
• Price to Book (P/B): 8.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.96
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 0.53
• Enterprise Value/Gross Profit: 5.68
• Enterprise Value/Ebitda: -3.12
• 1Y Price Target: $2.00
• Price Target Upside: 4.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 52 Neutral
• Price Target: $2.00 ▲(4.71%Upside)

Apyx Medical's overall stock score reflects significant financial performance weaknesses, particularly in profitability and cash flow. Despite technical indicators suggesting potential upward momentum and positive developments such as the FDA clearance for a new product, the company's negative P/E ratio and recent revenue declines weigh heavily on its valuation and overall score. Future success hinges on strategic execution and market acceptance of new products.

Positive Factors

Product Development

Apyx Medical announced it submitted a 510(k) for AYON, an all-in-one body contouring platform, ahead of schedule.

Technology Innovation

Renuvion is viewed as a differentiated helium-based plasma technology that can save significant time and provide superior clinical outcomes in several large, high-growth surgery markets.

Negative Factors

Market Uncertainty

There is uncertainty surrounding the timing of the company's ability to fully reengage with global customers and the overarching cosmetic market headwinds.

Apyx Medical Business Overview & Revenue Model

Company Description

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

How the Company Makes Money

Apyx Medical generates revenue through the sale of its proprietary medical devices and related products, with a significant portion of its income derived from its Renuvion/J-Plasma technology. This technology is marketed to plastic surgeons, dermatologists, and other medical professionals who utilize these devices in cosmetic and medical procedures. The company also earns revenue from service contracts and maintenance agreements associated with its equipment. Additionally, Apyx Medical may engage in strategic partnerships and collaborations to expand its market presence and enhance its product offerings, which can contribute to its overall earnings.

Apyx Medical Financial Statement Overview

Summary

Apyx Medical shows challenges in profitability with negative net income and cash flow issues. High leverage and diminishing equity raise concerns about financial stability.

Income Statement

Apyx Medical's income statement shows challenges in profitability with negative net income and EBIT margins over recent periods. The TTM gross profit margin is 51.6%, but net profit margin is negative at -42.4%, indicating significant losses. Revenue growth has been inconsistent, with a recent decline compared to the prior year. These factors suggest difficulties in achieving sustainable revenue growth and controlling costs.

Balance Sheet

The balance sheet highlights a high debt-to-equity ratio due to rising liabilities relative to equity, with a recent equity ratio of 17.5%. Although the company maintains a positive stockholders' equity, it faces potential risks due to leverage. The company's cash position is relatively strong compared to its debt, but diminishing equity poses a concern for financial stability.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating cash consumption rather than generation. The TTM operating cash flow to net income ratio is negative, reflecting cash challenges. Despite some financing inflows, the overall cash flow situation underscores a need for improved cash management and cost control.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	48.10M	52.35M	44.51M	48.52M	27.71M
Gross Profit	29.36M	33.76M	29.13M	33.60M	17.50M
EBITDA	-16.80M	-18.11M	-22.01M	-13.91M	-18.48M
Net Income	-23.46M	-18.71M	-23.28M	-15.20M	-11.91M
Balance Sheet
Total Assets	64.84M	79.24M	51.77M	68.72M	74.11M
Cash, Cash Equivalents and Short-Term Investments	31.74M	43.65M	10.19M	30.87M	41.91M
Total Debt	38.76M	38.50M	796.00K	305.00K	676.00K
Total Liabilities	50.51M	52.32M	13.98M	14.71M	10.25M
Stockholders Equity	14.21M	26.70M	37.58M	53.70M	63.72M
Cash Flow
Free Cash Flow	-18.77M	-5.78M	-21.29M	-11.17M	-16.65M
Operating Cash Flow	-18.05M	-5.25M	-20.28M	-10.45M	-16.07M
Investing Cash Flow	-722.00K	6.73M	-1.01M	-723.00K	-581.00K
Financing Cash Flow	6.75M	32.17M	217.00K	24.00K	-73.00K

Apyx Medical Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.91
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APYX, the sentiment is Neutral. The current price of 1.91 is below the 20-day moving average (MA) of 2.19, below the 50-day MA of 1.98, and above the 200-day MA of 1.49, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.89 is Neutral, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for APYX.

Apyx Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ECOR	63 Neutral	$51.67M	―	-276.15%	―	41.54%	42.59%
TELA	60 Neutral	$67.24M	―	-267.29%	―	12.78%	15.53%
NVNO	58 Neutral	$93.73M	―	-64.55%	―	―	29.64%
APYX	52 Neutral	$72.19M	―	-130.26%	―	-6.27%	16.76%
Sector *	51 Neutral	$7.30B	0.27	-62.71%	2.44%	15.02%	0.60%
MODD	―	$39.00M	―	-131.58%	―	―	―
RBOT	39 Underperform	$52.56M	―	-104.36%	―	―	-1455.58%

Apyx Medical Corporate Events

Apyx Medical Gains FDA Clearance for AYON System

On May 13, 2025, Apyx Medical Corporation announced it received FDA clearance for its AYON Body Contouring System, a pioneering all-in-one platform for aesthetic surgery. The system integrates multiple technologies to enhance surgical precision and patient outcomes, and its commercial launch is planned for the second half of 2025. This development positions Apyx Medical at the forefront of the growing body contouring market, driven by an increase in demand from patients experiencing rapid weight loss.

The most recent analyst rating on (APYX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Apyx Medical stock, see the APYX Stock Forecast page.